Retatrutide vs Mounjaro — Which is More Effective? (2025)

Retatrutide vs Mounjaro is one of the most searched comparisons in the GLP-1 research space right now. Both are produced by Eli Lilly, but they represent different generations of metabolic research compounds. Here is everything you need to know.

The Key Difference — Triple vs Dual Agonist

The fundamental difference between Retatrutide and Mounjaro (Tirzepatide) is the number of receptors targeted:

• Mounjaro (Tirzepatide) — Dual GLP-1/GIP agonist. Targets two receptors.
• Retatrutide — Triple GLP-1/GIP/Glucagon agonist. Targets three receptors.

The addition of glucagon receptor activation is what separates Retatrutide from Mounjaro. Glucagon activation increases resting energy expenditure — essentially increasing the rate at which the body burns calories even at rest — and promotes fat oxidation in the liver.

Clinical Trial Comparison

Retatrutide achieved comparable results in approximately one third of the time. Phase 3 trials are ongoing and expected to confirm or exceed these results.

Side Effect Profile Comparison

Both compounds share a similar gastrointestinal side effect profile — nausea, vomiting, diarrhoea and constipation being the most common. These are typically mild to moderate and most prominent during dose escalation.

The addition of glucagon agonism in Retatrutide does not appear to significantly increase the side effect burden based on Phase 2 data.

Which Should Researchers Choose?

For licensed researchers comparing the two compounds, Retatrutide offers the advantage of a more comprehensive receptor profile and potentially superior results based on available data. However as an investigational compound its long-term safety profile requires further study.

Mounjaro remains the gold standard approved medication, while Retatrutide represents the cutting edge of current research.